HEPATITIS C SKIP CONTENT ACCESS NAVIGATION SEARCH SITE ADVANCED HEALTH TOPICS DATA MEDIA CENTRE PUBLICATIONS GOVERNANCE LANGUAGE ENGLISH NEWS RELEASES PREVIOUS STATEMENTS NOTES MEDIA EVENTS DAYS MEETINGS FACT SHEETS FACT FILES QUESTIONS ANSWERS FEATURES MULTIMEDIA CONTACTS FACTS LIVER DISEASE CAUSED HEPATITIS C VIRUS THE VIRUS CAUSE ACUTE CHRONIC HEPATITIS RANGING SEVERITY MILD ILLNESS WEEKS BLOODBORNE VIRUS COMMON MODES INFECTION EXPOSURE INJECTION DRUG USE INJECTION TRANSFUSION BLOOD PEOPLE C NUMBER INFECTED DEVELOP CIRRHOSIS LIVER CANCER HEPATITIS HEPATOCELLULAR CARCINOMA ANTIVIRAL MEDICINES CURE PERSONS RISK DEATH DIAGNOSIS VACCINE RESEARCH AREA CAUSES CHRONIC INFECTION CLEAR MONTHS CHRONIC CIRRHOSIS OF THE LIVER GEOGRAPHICAL REGIONS EASTERN MEDITERRANEAN EUROPEAN REGIONS PREVALENCE WHO REGIONS CONCENTRATED CERTAIN POPULATIONS GENERAL MULTIPLE STRAINS TRANSMISSION DRUG SHARING REUSE INADEQUATE STERILIZATION MEDICAL EQUIPMENT SYRINGES NEEDLES HEALTHCARE MOTHER LESS SPREAD BREAST MILK WATER CASUAL CONTACT KISSING FOOD DRINKS ESTIMATES MODELLING INFECTIONS SYMPTOMS INCUBATION PERIOD INITIAL DO NOT EXHIBIT SYMPTOMATIC VOMITING ABDOMINAL DARK FAECES JOINT PAIN JAUNDICE SKIN THE WHITES SCREENING ACUTE PHASE THOSE PEOPLE GO ON THE INFECTION REMAINS ASYMPTOMATIC DECADES LIVER DAMAGE IN 2 ANTIBODIES SEROLOGICAL TEST THE TEST POSITIVE NUCLEIC ACID TEST RIBONUCLEIC ACID CONFIRM STRONG IMMUNE RESPONSE THE NEED LONGER PERSON SHOULD ASSESSMENT DEGREE DONE LIVER BIOPSY VARIETY LABORATORY GENOTYPE RESPOND DIFFERENTLY POSSIBLE USED TO GUIDE DECISIONS MANAGEMENT THE DISEASE TESTED PREVENT PROBLEMS RISK OF INFECTION INTRANASAL INFECTED BLOOD INVASIVE PROCEDURES INFECTION CONTROL CHILDREN MOTHERS SEXUAL PARTNERS PEOPLE WITH HIV PRISONERS PREVIOUSLY INCARCERATED TATTOOS LIVING HIV GLOBALLY EVIDENCE PAST PRESENT CONVERSELY LIVER DISEASES MAJOR MORBIDITY AND MORTALITY ALWAYS THE IMMUNE THE GOAL THE CURE RATE DEPENDS FACTORS THE STRAIN TYPE THE STANDARD CARE CHANGING SOFOSBUVIR DACLATASVIR THE WHO RATES ABOVE MUCH MORE SAFER OLDER THERAPIES THERAPY DAAS SHORTER LIMITED ROLE PEGYLATED INTERFERON RIBAVIRIN SCENARIOS PRODUCTION COST PRICES DRAMATICALLY INTRODUCTION NEEDS ENSURE LEAD GREATER PREVENTION PRIMARY PREVENTION THEREFORE SETTINGS HIGHER SEXUAL EXAMPLE INTERVENTIONS HAND HYGIENE SURGICAL HAND HAND WASHING SAFE HEALTH CARE HANDLING DISPOSAL SHARPS PROVISION COMPREHENSIVE DRUGS TESTING DONATED HEPATITIS B TRAINING PROMOTION CONSISTENT TERTIARY PREVENTION EDUCATION OPTIONS COINFECTION HEPATITIS VIRUSES PROTECT MEDICAL MANAGEMENT ANTIVIRAL THERAPY REGULAR MONITORING CHRONIC LIVER DISEASE GUIDELINES COMPLEMENT EXISTING GUIDANCE VIRUSES GOVERNMENT OFFICIALS HELP EXPAND PATIENTS RECOMMENDATIONS AREAS DISCUSS HALF REACHED SUMMARY SEROLOGY TESTING INDIVIDUALS POPULATION HIGH HISTORY OF DETECTION PERFORMED RNA WHETHER START ALCOHOL USE REDUCE MODERATE ALCOHOL INTAKE FOR ALL VIRUS INFECTION BEHAVIOURAL REDUCTION INTERVENTION FIBROSIS AMINOTRANSFERASE RATIO INDEX HEPATIC FIBROSIS RATHER RESOURCES ELASTOGRAPHY FIBROTEST ADULTS EXCEPT GROUPS OF PEOPLE WHOM ALTERNATIVE REGIMEN OR 6 TELAPREVIR BOCEPREVIR SHOWS ADVERSE EFFECTS CURES STATUS GUIDELINE DEVELOPMENT GROUP AVAILABLE DETERMINE EFFECTIVE THE 6 THE WORLD ASSEMBLY SECTOR STRATEGY VIRAL HEPATITIS HIGHLIGHTS CRITICAL ROLE UNIVERSAL HEALTH COVERAGE TARGETS SUSTAINABLE DEVELOPMENT GOALS VISION PUBLIC HEALTH PROBLEM GLOBAL DEATHS TAKEN SECRETARIAT REACH SUPPORT MOVING SUSTAINABLE DEVELOPMENT AGENDA 2030 RAISING AWARENESS PARTNERSHIPS POLICY SCALING ORGANIZES WORLD HEPATITIS DAY INCREASE AWARENESS UNDERSTANDING ACT NOW EVENT NOTICE MESSAGES INFOGRAPHIC GLOBAL HEALTH HEPATITIS D HEPATITIS E MONITORING AND EVALUATION OUTBREAKS DEVELOPMENT OF NATIONAL PLANS ALL NEWS YOU ARE HERE QUICK LINKS SITEMAP PROJECTS FAQS EMPLOYMENT FEEDBACK PRIVACY SCAMS REGIONAL OFFICES AFRICAN REGION WHO REGION THE AMERICAS ASIA REGION EUROPEAN REGION WESTERN PACIFIC REGION EMAIL ADDRESS SIGN UPDATES